QN-03

QN-03 is an investigational drug candidate being developed by Qnovia (formerly Respira Technologies) for the treatment of migraine and acute pain management. The product utilizes Qnovia's proprietary RespiRx platform, an ultrasonic nebulization technology designed to deliver medications via the pulmonary route for rapid systemic absorption. This delivery modality is intended to provide a faster onset of action compared to traditional oral therapies, which is critical for acute pain relief. QN-03 is currently in the formulation and delivery scoping stage, where the specific drug-device combination is being optimized. While the exact active pharmaceutical ingredient (API) has not been publicly disclosed, the program leverages the company's expertise in high-precision aerosol delivery for neurological and respiratory indications.